| Title: |
Cost-effectiveness of low-dose colchicine in patients with chronic coronary disease in the netherlands |
| Authors: |
Fiolet, Aernoud T L; Keusters, Willem; Blokzijl, Johan; Nidorf, S Mark; Eikelboom, John E; Budgeon, Charley A; Tijssen, Jan G P; Römer, Tjeerd; Westendorp, Iris; Cornel, Jan Hein; Thompson, Peter L; Frederix, Geert W J; Mosterd, Arend; de Wit, G Ardine |
| Source: |
Fiolet, A T L, Keusters, W, Blokzijl, J, Nidorf, S M, Eikelboom, J E, Budgeon, C A, Tijssen, J G P, Römer, T, Westendorp, I, Cornel, J H, Thompson, P L, Frederix, G W J, Mosterd, A & de Wit, G A 2025, 'Cost-effectiveness of low-dose colchicine in patients with chronic coronary disease in the netherlands', European Heart Journal : Quality of Care & Clinical Outcomes, vol. 11, no. 1, pp. 89-96. https://doi.org/10.1093/ehjqcco/qcae021 |
| Publication Year: |
2025 |
| Description: |
AIMS: Recent trials have shown that low-dose colchicine (0.5 mg once daily) reduces major cardiovascular events in patients with acute and chronic coronary syndromes. We aimed to estimate the cost-effectiveness of low-dose colchicine therapy in patients with chronic coronary disease when added to standard background therapy. METHODS AND RESULTS: This Markov cohort cost-effectiveness model used estimates of therapy effectiveness, transition probabilities, costs and quality of life obtained from the Low-dose Colchicine 2 (LoDoCo2) trial, as well as meta-analyses and public sources. In this trial, Low-dose colchicine was added to standard of care and compared to placebo. The main outcomes were cardiovascular events including myocardial infarction, stroke and coronary revascularisation, quality-adjusted life-year (QALY), the cost per QALY gained (incremental cost-effectiveness ratio), and net monetary benefit. In the model, low-dose colchicine therapy yielded 0.04 additional QALYs compared with standard of care at an incremental cost of €455 from a societal perspective and €729 from a healthcare perspective, resulting in a cost per QALY gained of €12,176/QALY from a societal perspective and €19,499/QALY from a healthcare perspective. Net monetary benefit was €1,414 from a societal perspective and €1,140 from a healthcare perspective. Low-dose colchicine has a 96% and 94% chance of being cost effective, from respectively a societal and healthcare perspective when using a willingness to pay of €50,000/QALY. Net monetary benefit would decrease below zero when annual low-dose colchicine costs would exceed an annual cost of €221 per patient. CONCLUSION: Adding low-dose colchicine to standard of care in patients with chronic coronary disease is cost-effective according to commonly accepted thresholds in Europe and Australia and compares favourably in cost-effectiveness to other drugs used in chronic coronary disease. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISSN: |
2058-1742 |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/38486357; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/1871.1/ed95d31f-301f-496c-8a95-d0c77c929147; info:eu-repo/semantics/altIdentifier/pissn/2058-1742; info:eu-repo/semantics/altIdentifier/eissn/2058-1742 |
| DOI: |
10.1093/ehjqcco/qcae021 |
| Availability: |
https://research.vu.nl/en/publications/ed95d31f-301f-496c-8a95-d0c77c929147; https://doi.org/10.1093/ehjqcco/qcae021; https://hdl.handle.net/1871.1/ed95d31f-301f-496c-8a95-d0c77c929147; https://www.scopus.com/pages/publications/85215854311; http://www.scopus.com/inward/citedby.url?scp=85215854311&partnerID=8YFLogxK; https://www.scopus.com/pages/publications/85215854311#tab=citedBy |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.FD5861BA |
| Database: |
BASE |